Emerging therapies for acute myeloid leukemia
Abstract Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity. Despite the advances in our understanding of its pathobiology, the chemotherapy-directed management has remained largely unchanged in the past 40 years. However, various novel agents have demonstrated cl...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-04-01
|
| Series: | Journal of Hematology & Oncology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13045-017-0463-6 |
| _version_ | 1818195122168266752 |
|---|---|
| author | Caner Saygin Hetty E. Carraway |
| author_facet | Caner Saygin Hetty E. Carraway |
| author_sort | Caner Saygin |
| collection | DOAJ |
| description | Abstract Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity. Despite the advances in our understanding of its pathobiology, the chemotherapy-directed management has remained largely unchanged in the past 40 years. However, various novel agents have demonstrated clinical activity, either as single agents (e.g., isocitrate dehydrogenase (IDH) inhibitors, vadastuximab) or in combination with standard induction/consolidation at diagnosis and with salvage regimens at relapse. The classes of agents described in this review include novel cytotoxic chemotherapies (CPX-351 and vosaroxin), epigenetic modifiers (guadecitabine, IDH inhibitors, histone deacetylase (HDAC) inhibitors, bromodomain and extraterminal (BET) inhibitors), FMS-like tyrosine kinase receptor 3 (FLT3) inhibitors, and antibody-drug conjugates (vadastuximab), as well as cell cycle inhibitors (volasertib), B-cell lymphoma 2 (BCL-2) inhibitors, and aminopeptidase inhibitors. These agents are actively undergoing clinical investigation alone or in combination with available chemotherapy. |
| first_indexed | 2024-12-12T01:13:10Z |
| format | Article |
| id | doaj.art-0722f99891ec43d79adba1e8b610944b |
| institution | Directory Open Access Journal |
| issn | 1756-8722 |
| language | English |
| last_indexed | 2024-12-12T01:13:10Z |
| publishDate | 2017-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj.art-0722f99891ec43d79adba1e8b610944b2022-12-22T00:43:24ZengBMCJournal of Hematology & Oncology1756-87222017-04-0110111410.1186/s13045-017-0463-6Emerging therapies for acute myeloid leukemiaCaner Saygin0Hetty E. Carraway1Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland ClinicDepartment of Hematology and Oncology, Taussig Cancer Institute, Cleveland ClinicAbstract Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity. Despite the advances in our understanding of its pathobiology, the chemotherapy-directed management has remained largely unchanged in the past 40 years. However, various novel agents have demonstrated clinical activity, either as single agents (e.g., isocitrate dehydrogenase (IDH) inhibitors, vadastuximab) or in combination with standard induction/consolidation at diagnosis and with salvage regimens at relapse. The classes of agents described in this review include novel cytotoxic chemotherapies (CPX-351 and vosaroxin), epigenetic modifiers (guadecitabine, IDH inhibitors, histone deacetylase (HDAC) inhibitors, bromodomain and extraterminal (BET) inhibitors), FMS-like tyrosine kinase receptor 3 (FLT3) inhibitors, and antibody-drug conjugates (vadastuximab), as well as cell cycle inhibitors (volasertib), B-cell lymphoma 2 (BCL-2) inhibitors, and aminopeptidase inhibitors. These agents are actively undergoing clinical investigation alone or in combination with available chemotherapy.http://link.springer.com/article/10.1186/s13045-017-0463-6AMLCPX-351VosaroxinGuadecitabineIDHHDAC |
| spellingShingle | Caner Saygin Hetty E. Carraway Emerging therapies for acute myeloid leukemia Journal of Hematology & Oncology AML CPX-351 Vosaroxin Guadecitabine IDH HDAC |
| title | Emerging therapies for acute myeloid leukemia |
| title_full | Emerging therapies for acute myeloid leukemia |
| title_fullStr | Emerging therapies for acute myeloid leukemia |
| title_full_unstemmed | Emerging therapies for acute myeloid leukemia |
| title_short | Emerging therapies for acute myeloid leukemia |
| title_sort | emerging therapies for acute myeloid leukemia |
| topic | AML CPX-351 Vosaroxin Guadecitabine IDH HDAC |
| url | http://link.springer.com/article/10.1186/s13045-017-0463-6 |
| work_keys_str_mv | AT canersaygin emergingtherapiesforacutemyeloidleukemia AT hettyecarraway emergingtherapiesforacutemyeloidleukemia |